Table 2.
Treatments beyond the first-line chemotherapy.
| Whole study population |
Matched population |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 216) | Folfirinox (n = 107) | Gemcitabine/ nab-paclitaxel (n = 109) | p value | Total (n = 98) | Folfirinox (n = 49) | Gemcitabine/nab-paclitaxel (n = 49) | Adjusted p value | |
| Second-line chemotherapy | 140 (64.8%) | 77 (72%) | 63 (57.8%) | 0.042 | 68 (69.4%) | 35 (71.4%) | 33 (67.3%) | 0.82 |
| LV5FU2 | 1 | 0 | 1 | – | 1 | 0 | 1 | – |
| 5FU-cisplatin | 4 | 2 | 2 | – | 3 | 1 | 2 | – |
| Folfox | 26 | 0 | 26 | – | 11 | 0 | 11 | – |
| Folfiri | 12 | 0 | 12 | – | 6 | 0 | 6 | – |
| Gemzar | 24 | 24 | 0 | – | 7 | 7 | 0 | – |
| Gemox | 1 | 0 | 1 | – | 0 | 0 | 0 | – |
| Folfiri3 | 12 | 5 | 7 | – | 7 | 4 | 3 | – |
| Folfirinox | 14 | 0 | 14 | – | 10 | 0 | 10 | – |
| Gemcitabine/ nab-paclitaxel | 46 | 46 | 0 | – | 23 | 23 | 0 | – |
| Sequence folfirinox–gemcitabine/nab-paclitaxel versus reverse sequence | 60 (27.8%) | 46 (43%) | 14 (12.8%) | <0.001 | 33 (33.7%) | 23 (46.9%) | 10 (20.4%) | 0.009* |
| Third-line chemotherapy | 42 (19.4%) | 24 (22.4%) | 18 (16.5%) | 0.35 | 21 (21.4%) | 12 (24.5%) | 9 (18.4%) | 0.62* |
*
McNemar test.